BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2021

View Archived Issues

Post-chemo bone marrow regeneration elucidated

Read More

Taiho begins phase II study of TAS-117 in advanced solid tumors with germline PTEN mutations

Read More

Roche initiates phase III study of glofitamab for relapsed or refractory DLBCL

Read More

Pain on the brain

Read More

Neurons contribute to their own lack of regeneration

Read More

Astrocytes are more inflammatory in bipolar disease

Read More

Headless hemagglutinin induces broad influenza antibodies

Read More

Study sponsors discontinue testing of razuprotafib in I-SPY COVID trial

Read More

CAUSALITY study of Xla-1 shows safety in healthy volunteers and starts enrolling obese patients

Read More

FDA approves phase III study of proxalutamide in COVID-19

Read More

Gene therapy for TMPRSS3 hearing loss shows promise with late intervention in mouse model

Read More

Neumifil is efficacious in hamster model of COVID-19 infection

Read More

CytoDyn reports phase III data on leronlimab in critically ill COVID-19 patients

Read More

Innovation studies brilacidin in phase II trial for hospitalized patients with COVID-19

Read More

Melatonin repairs PNI through activation of the Shh signaling pathway in Schwann cells

Read More

Roche patents mGlu4 receptor negative allosteric modulators

Read More

Aligos Therapeutics discloses new antivrals for hepatitis

Read More

BiSiChem identifies RIPK1 inhibitors

Read More

Anti-inflammatory peptide amphiphiles reduce inflammation in Crohn's disease-like ileitis model

Read More

Incyte discloses CDK2/cyclin E inhibitors

Read More

Crinetics Pharmaceuticals synthesizes new somatostatin SST5 receptor agonists

Read More

JTP-109192 shows cholesterol-lowering effect in hyperlipidemic mice

Read More

FDA grants accelerated approval to Yescarta for relapsed or refractory follicular lymphoma

Read More

Abivax stops phase IIb/III trial of ABX-464 in high-risk COVID-19 based on DSMB recommendation

Read More

Roche withdraws Tecentriq U.S. indication for prior-platinum treated metastatic urothelial carcinoma

Read More

REGN1908-1909 ameliorates bronchoconstriction in patients with cat-allergy asthma

Read More

Bavarian Nordic reports preclinical data on COVID-19 vaccine candidate ABNCoV2

Read More

Seres discontinues enrollment in MCGRAW study of SER-401 in metastatic melanoma

Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing